Dermata Therapeutics Warrant Stock Performance
| DRMAW Stock | USD 0.02 0.0001 0.51% |
On a scale of 0 to 100, Dermata Therapeutics holds a performance score of 1. The firm shows a Beta (market volatility) of 3.43, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Dermata Therapeutics will likely underperform. Please check Dermata Therapeutics' maximum drawdown, as well as the relationship between the expected short fall and day typical price , to make a quick decision on whether Dermata Therapeutics' price patterns will revert.
Risk-Adjusted Performance
Weak
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Dermata Therapeutics Warrant are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of fairly uncertain basic indicators, Dermata Therapeutics showed solid returns over the last few months and may actually be approaching a breakup point. ...more
1 | Why Dermata Therapeutics Inc. Equity Warrant is moving today - Trade Risk Assessment Daily Chart Pattern Signals - newser.com | 09/18/2025 |
2 | Acquisition by Van Hoose Kyri K. of 78741 shares of Dermata Therapeutics subject to Rule 16b-3 | 10/17/2025 |
3 | Can Dermata Therapeutics Inc. Equity Warrant stock resist market sell offs - July 2025 Market Mood Precise Swing Trade Entry Alerts - newser.com | 11/14/2025 |
4 | Returns Recap Will Dermata Therapeutics Inc. stock see insider buying - Weekly Trade Review Detailed Earnings Play Strategies - B NI V | 11/26/2025 |
5 | Tenaya Therapeutics proposes unit offering of common stock and warrants - Stock Titan | 12/11/2025 |
6 | Dermata lines up as much as 12.4M to help launch OTC acne kit - Stock Titan | 12/24/2025 |
7 | Acquisition by Fisher Mary of 2500 shares of Dermata Therapeutics at 2.18 subject to Rule 16b-3 | 01/02/2026 |
Dermata Therapeutics Relative Risk vs. Return Landscape
If you would invest 2.90 in Dermata Therapeutics Warrant on November 2, 2025 and sell it today you would lose (0.95) from holding Dermata Therapeutics Warrant or give up 32.76% of portfolio value over 90 days. Dermata Therapeutics Warrant is currently producing 0.3283% returns and takes up 15.3413% volatility of returns over 90 trading days. Put another way, most equities are less risky on the basis of their return distribution than Dermata, and majority of traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Dermata Therapeutics Target Price Odds to finish over Current Price
The tendency of Dermata Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.02 | 90 days | 0.02 | about 68.43 |
Based on a normal probability distribution, the odds of Dermata Therapeutics to move above the current price in 90 days from now is about 68.43 (This Dermata Therapeutics Warrant probability density function shows the probability of Dermata Stock to fall within a particular range of prices over 90 days) .
Assuming the 90 days horizon the stock has the beta coefficient of 3.43 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Dermata Therapeutics will likely underperform. Additionally Dermata Therapeutics Warrant has an alpha of 0.8218, implying that it can generate a 0.82 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Dermata Therapeutics Price Density |
| Price |
Predictive Modules for Dermata Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Dermata Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Dermata Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Dermata Therapeutics is not an exception. The market had few large corrections towards the Dermata Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Dermata Therapeutics Warrant, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Dermata Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.82 | |
β | Beta against Dow Jones | 3.43 | |
σ | Overall volatility | 0 | |
Ir | Information ratio | 0.06 |
Dermata Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Dermata Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Dermata Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Dermata Therapeutics had very high historical volatility over the last 90 days | |
| Dermata Therapeutics has some characteristics of a very speculative penny stock | |
| Dermata Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (12.29 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Dermata Therapeutics generates negative cash flow from operations | |
| Latest headline from news.google.com: Trend Report What is Purple Biotech Ltd Depositary Receipts market position - 2025 Risk Factors Weekly Top Performers Watchlists - baoquankhu1.vn |
Dermata Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Dermata Stock often depends not only on the future outlook of the current and potential Dermata Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Dermata Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
| Common Stock Shares Outstanding | 153 K | |
| Cash And Short Term Investments | 3.2 M |
Dermata Therapeutics Fundamentals Growth
Dermata Stock prices reflect investors' perceptions of the future prospects and financial health of Dermata Therapeutics, and Dermata Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Dermata Stock performance.
| Return On Equity | -2.03 | ||||
| Return On Asset | -0.96 | ||||
| EBITDA | (12.29 M) | ||||
| Net Income | (12.29 M) | ||||
| Total Debt | 1.97 M | ||||
| Book Value Per Share | 4.69 X | ||||
| Cash Flow From Operations | (11.16 M) | ||||
| Earnings Per Share | (2.16) X | ||||
| Total Asset | 3.53 M | ||||
| Retained Earnings | (65.68 M) | ||||
| Working Capital | 1.56 M | ||||
About Dermata Therapeutics Performance
Evaluating Dermata Therapeutics' performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Dermata Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Dermata Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (3.13) | (3.29) | |
| Return On Capital Employed | (7.21) | (6.85) | |
| Return On Assets | (3.13) | (3.29) | |
| Return On Equity | (9.05) | (8.60) |
Things to note about Dermata Therapeutics performance evaluation
Checking the ongoing alerts about Dermata Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Dermata Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Dermata Therapeutics had very high historical volatility over the last 90 days | |
| Dermata Therapeutics has some characteristics of a very speculative penny stock | |
| Dermata Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (12.29 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Dermata Therapeutics generates negative cash flow from operations | |
| Latest headline from news.google.com: Trend Report What is Purple Biotech Ltd Depositary Receipts market position - 2025 Risk Factors Weekly Top Performers Watchlists - baoquankhu1.vn |
- Analyzing Dermata Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Dermata Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Dermata Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Dermata Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Dermata Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Dermata Therapeutics' stock. These opinions can provide insight into Dermata Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Dermata Stock Analysis
When running Dermata Therapeutics' price analysis, check to measure Dermata Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Dermata Therapeutics is operating at the current time. Most of Dermata Therapeutics' value examination focuses on studying past and present price action to predict the probability of Dermata Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Dermata Therapeutics' price. Additionally, you may evaluate how the addition of Dermata Therapeutics to your portfolios can decrease your overall portfolio volatility.